C2CD3

Across TCGA pan-cancer cohorts, C2CD3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of C2CD3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where C2CD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types C2CD3 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and PDAC are the cancer types where C2CD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C2CD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	−0.134	.005	6	view →
HNSC	All	All	−0.334	.009	4	view →
PDAC	Male	All	−0.492	.011	2	view →
LUAD	Female	All	−0.231	<.001	2	view →
CCRCC	Female	III,IV	+0.280	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

C2CD3–LSCC

Open the LSCC breakdown →